We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
FDA Commissioner Scott Gottlieb once again chastised brand-name companies that slow-walk federal procedures and use regulations to delay the entry of generic competitors. Read More
A group of investment funds sued Allergan, accusing the company of artificially inflating its stock by conspiring with other manufacturers of generic drugs. Read More
A Stanford law professor said the president already has the authority to provide for administration of unapproved drugs to military personnel — a power similar to that proposed for the Department of Defense in pending federal legislation that has raised alarms in Congress. Read More